OKYO Pharma (OKYO) grants CSO 3,363 common shares at $1.49

Rhea-AI Filing Summary

Patil Rajkumar V. reported acquisition or exercise transactions in this Form 4 filing.

OKYO Pharma Ltd reported that Chief Scientific Officer Rajkumar V. Patil received a grant of 3,363 shares of common stock on July 27, 2026, at $1.49 per share. Following this award, he directly owns 20,030 shares of OKYO Pharma common stock.

Insider Trade Summary

Net Buyer: 3,363 shares

Net Buy 1 txn

Insider Patil Rajkumar V.

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	3,363	$1.49	$5K

Holdings After Transaction: COMMON STOCK — 20,030 shares (Direct)

Key Figures

Shares granted: 3,363 shares Grant price: $1.49 per share Total holdings after grant: 20,030 shares

3 metrics

Shares granted 3,363 shares Grant/award of common stock on July 27, 2026

Grant price $1.49 per share Price per share for the 3,363-share common stock grant

Total holdings after grant 20,030 shares Direct ownership of OKYO Pharma common stock following the award

Key Terms

Grant, award, or other acquisition, direct ownership, acquired_disposed_code

3 terms

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

direct ownership financial

""ownership_type": "direct""

acquired_disposed_code financial

""acquired_disposed_code": "A""

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 04:45 PM Accepted by SEC EDGAR 07/29/2026 - 04:45 PM Learn about SEC filing dates

FAQ

What insider transaction did OKYO (OKYO) report for Rajkumar V. Patil?

OKYO reported that Chief Scientific Officer Rajkumar V. Patil received a grant of 3,363 common shares on July 27, 2026, at $1.49 per share. After this award, his direct holdings increased to 20,030 shares of OKYO Pharma common stock.

How many OKYO (OKYO) shares did the Chief Scientific Officer acquire and at what price?

The Chief Scientific Officer acquired 3,363 shares of OKYO Pharma common stock at a price of $1.49 per share. This was reported as a grant or award transaction, not as an open-market purchase, and increased his direct ownership position.

What are Rajkumar V. Patil’s total OKYO (OKYO) holdings after this transaction?

Following the reported grant, Rajkumar V. Patil directly holds 20,030 shares of OKYO Pharma common stock. This figure reflects his total direct ownership immediately after the 3,363-share award on July 27, 2026, as disclosed in the insider report.

What type of transaction was reported for OKYO (OKYO) common stock?

The transaction is classified as a “Grant, award, or other acquisition” of common stock under transaction code A. It is a non-derivative acquisition, meaning the 3,363 shares were received directly rather than through exercising options or other derivatives.

Was the OKYO (OKYO) insider transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating this grant was not reported as being made under a Rule 10b5-1 trading plan. It appears as a standard equity award to the Chief Scientific Officer.

Is the OKYO (OKYO) share ownership reported as direct or indirect for this insider?

The 20,030 shares held by Rajkumar V. Patil after the transaction are reported as direct ownership. The ownership code is listed as “D,” and there is no linked footnote indicating that an external entity holds voting or investment power over these shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patil Rajkumar V.

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/27/2026		A		3,363	A	$1.49	20,030	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Raj Patil	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)